Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma

Abstract : The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.
Type de document :
Article dans une revue
Blood, American Society of Hematology, 2010, 115 (16), pp.3215-23. 〈10.1182/blood-2009-06-230250〉
Liste complète des métadonnées

Littérature citée [44 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00481726
Contributeur : Georges Guellaen <>
Soumis le : jeudi 24 juin 2010 - 11:37:57
Dernière modification le : vendredi 6 juillet 2018 - 01:25:30
Document(s) archivé(s) le : lundi 27 septembre 2010 - 10:49:34

Fichiers

2009_pott_blood.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Christiane Pott, Eva Hoster, Marie-Hélène Delfau-Larue, Kheira Beldjord, Sebastian Böttcher, et al.. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma. Blood, American Society of Hematology, 2010, 115 (16), pp.3215-23. 〈10.1182/blood-2009-06-230250〉. 〈inserm-00481726〉

Partager

Métriques

Consultations de la notice

1451

Téléchargements de fichiers

876